ImpactGuru’s pitch to a frightened family is simple: list a hospital bill, pay nothing to the platform, and let strangers cover it. In the fiscal year it also disclosed revenue of ₹103.5 crore (about $10.8 million) and a net loss of ₹24.2 crore, as per its FY25 financials reviewed by Inc42 — a “free” product that still costs the company more than it earns.
The same year that loss became public, a Mumbai social worker accused ImpactGuru’s own co-founder of helping siphon ₹4.5 crore raised for a sick infant. Police later closed the case, finding no evidence. Both facts sit inside the same platform, and both point at the same question this piece tries to answer: what does it actually take to move money from a stranger’s wallet to a hospital counter, at scale, in India.
Quick facts
| Company | ImpactGuru (ImpactGuru Technology Ventures Pvt Ltd, part of CarePal Group) |
| Founded | 2014 (incorporated as a private limited company in January 2015) |
| Founder(s) | Piyush Jain (co-founder & CEO) and Khushboo Jain (co-founder & COO); Vikas Kaul co-founded parent CarePal Group in 2023 |
| Businesses | Medical and social crowdfunding (ImpactGuru.com); health insurance (CarePal Secure); lending marketplace (CarePal Money) |
| Latest FY revenue | ₹103.5 crore (FY25, per Inc42’s review of its filings) |
| Latest FY profit/loss | Net loss of ₹24.2 crore (FY25, per Inc42) |
| Listed | Private; no IPO announced as of September 2026 |
| Market value / last valuation | Reportedly about $92.3 million (roughly ₹886 crore) as of February 2025, per Tracxn — a single-source estimate, not company-disclosed |
| Key shareholders / CEO | Piyush Jain (CEO); investors including RB Investments, Apollo Hospitals Enterprise and Shorooq Partners |
What they do
ImpactGuru runs a crowdfunding website and app where individuals list a cause — most often a medical emergency such as a transplant, cancer treatment or a rare-disease drug that costs crores per dose — and ask family, friends and strangers to fund it directly, in small amounts, without collateral or a bank’s credit check. Registered non-profits can also run pooled fundraising campaigns for causes such as disaster relief. The company states on its own site that it has built a base of “50 lakh+” donors, has hosted “2 lakh+” fundraisers, and has helped “50,000+” patients, figures given without a fixed start date (ImpactGuru.com, accessed September 2026). Alongside the fundraising product, the company has since 2023 grouped itself under a parent brand, CarePal Group, which also sells health insurance (CarePal Secure) and consumer medical loans (CarePal Money) to the same distressed-patient audience.
The origin
Piyush Jain was studying public policy at Harvard’s Kennedy School, researching non-equity ways to finance social ventures, when he concluded that crowdfunding was close to non-existent in India even though the need for it was obvious. His own account, given to Startup Talky, cites how little of the Indian population carried any form of health expense cover at the time — a gap a bank loan or an insurance policy would not close quickly enough for an emergency. He built the first version of the idea at Harvard’s Innovation Lab in 2014 and brought it to Mumbai with his wife, Khushboo Jain. Piyush’s background was in finance and consulting — spells at J.P. Morgan, Boston Consulting Group and Ernst & Young preceded Harvard. Khushboo came from the opposite direction: she had worked as a fashion marketer for Valiram in Singapore on brands including Hackett, La Martina and Jimmy Choo, and had done merchandising work with the designer Manish Malhotra. The pairing put a finance-trained dealmaker and a brand-and-relationships operator on the same founding team, which is unusual for a fintech-adjacent platform and shows up later in how heavily the company has leaned on partnerships — hospitals, NGOs, payment companies — rather than pure technology, to grow.
The struggle years
Two dated episodes show where the model has actually been tested.
- 2020-21, forced fee pivot: ImpactGuru’s original business, per Startup Talky’s account, ran on a platform fee taken out of every campaign. By 2021 the company had moved its personal medical campaigns to a “0%” platform fee, asking donors to leave an optional tip instead — a monetisation model it still runs today. The switch tracked a broader shift in Indian crowdfunding where rivals were also racing to advertise zero fees, meaning ImpactGuru gave up a direct revenue line under competitive pressure rather than by choice.
- February 2024 to July 2025, the Baby Inara case: a social worker, Arif Shaikh, filed a complaint alleging that ₹4.5 crore raised for the treatment of an infant, “Inara,” diagnosed with spinal muscular atrophy, was diverted rather than spent on her care. Mumbai police registered a first information report in November 2024 against ImpactGuru co-founder and CEO Piyush Jain and the child’s parents, Naufil Kazi and Nikhat Khan, on charges of cheating, forgery and criminal conspiracy (NewsX, November 2024). ImpactGuru publicly rejected the allegations and said ₹2.2 crore had been raised and accounted for (Free Press Journal, 2024). By July 2025, the Matunga police station had filed a Summary B closure report with the magistrate’s court in Kurla, stating it found no evidence to support the complaint and that the case appeared intended to damage the fundraiser’s and the company’s reputation (Republic World, 2025).
Neither episode broke the company. But together they describe its two structural weak points: a revenue model that depends on donors giving something the platform cannot legally demand, and a verification process that has to move faster than a police investigation ever will.
The turning point
The clearest before-and-after moment on record is the first wave of COVID-19 in 2020. ImpactGuru’s core product until then was built around individually named medical campaigns — a person, a diagnosis, a hospital. The pandemic forced it toward something closer to disaster relief: co-founder Khushboo Jain told YourStory in November 2020 that the platform had raised more than ₹15 crore to support daily-wage workers and others left without income during the lockdowns. Separately, the company took part in a matched-giving programme with the ACT (Action Covid-19 Team) collective, which added roughly ₹40 lakh on top of donor contributions toward hospital protective equipment, a top-up of about 20% on the underlying gift, according to Startup Talky’s account of the partnership. Before that moment, ImpactGuru was a niche medical-fundraising tool used mostly by patients who already knew about it. After it, the same mechanism — post a need, ask strangers, disburse fast — was being used for rent, food and factory wages, at a scale the company had not been built to serve, and donor numbers grew from there.
The money behind it
ImpactGuru has raised a reported $21.2 million in total across nine rounds from roughly 20 disclosed investors, per Tracxn’s funding tracker (accessed September 2026). Individual round sizes are inconsistently reported across trackers and are not repeated here for that reason, but the named backers and what each brought are well documented:
- RB Investments (Singapore): an early backer from the company’s 2016 seed round, giving ImpactGuru its first institutional capital and a Southeast Asian investor base years before it had Indian revenue to show.
- Apollo Hospitals Enterprise: a strategic investor from a 2018 round — a hospital chain funding the platform that sends it patients, which gave ImpactGuru clinical credibility and a direct line into one of India’s largest private hospital networks.
- Shorooq Partners: a Gulf-region investor that backed a later round, aligning with ImpactGuru’s push into GCC markets, where a large Indian diaspora donates to causes back home.
- Beyond Next Ventures, 100Unicorns, Beams Fintech Fund, Dream Incubator and Earlsfield Capital: among the investors named in ImpactGuru’s most recent disclosed round, in February 2025, per Tracxn.
Tracxn puts ImpactGuru’s valuation at roughly $92.3 million as of that February 2025 round — a figure that is “reported” by a data aggregator rather than confirmed by the company, and which this piece could not corroborate against a second independent source, so it should be read as an estimate rather than a fact.
How it makes money
The economics are less generous than the “0% fee” headline suggests, and the gap between the two is the part people get wrong.
- Personal medical campaigns: ImpactGuru charges no platform fee and instead asks donors to add a voluntary tip on top of their gift, per the company’s own pricing pages.
- Payment processing: banks and payment gateways still deduct roughly 2.5-4% plus GST on every domestic transaction, and international donors paying in dollars face an additional per-transaction charge and a flat wire-transfer fee, none of which is waived by the “0%” platform fee (ImpactGuru.com pricing and FAQ pages).
- Pooled and NGO campaigns: registered non-profits running pooled fundraisers are charged a materially higher platform fee, disclosed on ImpactGuru’s own fee schedule, rather than the 0% rate given to individual medical campaigns.
- Premium services: the company sells add-ons — professional video production, dedicated campaign management and marketing push — as fixed-fee upgrades on top of any campaign, regardless of the base fee tier.
- Cross-sell: under the CarePal umbrella, the same distressed-patient audience is also offered health insurance and medical loans, a second and third revenue line built on top of the crowdfunding traffic.
The upshot: the product that carries ImpactGuru’s brand and drives most of its campaign volume — free, individual medical fundraisers — is the one least likely to generate direct fee revenue. The money instead comes from payment-processing float, the NGO and pooled-cause fee tier, premium services, and the newer insurance and lending cross-sell, a mix the company does not break out publicly by rupee amount.
The numbers
Public disclosure on ImpactGuru’s financials is thin and comes largely from data aggregators reading its regulatory filings rather than from the company itself, so the table below carries only what could be confirmed from an opened source, and gaps are left as gaps rather than filled in.
| Fiscal year | Revenue (₹ crore) | Net profit / (loss) (₹ crore) |
| FY21 | ~35.5 | not disclosed in sources reviewed |
| FY24 | 99.9 | not disclosed in sources reviewed |
| FY25 | 103.5 | (24.2) |
- FY21 revenue: about ₹35.5 crore (~$4.76 million at the time), per CB Insights’ financial summary — the only year in the data reviewed where a clean revenue figure was available without a corresponding disclosed loss.
- FY24 revenue: ₹99.9 crore, per Inc42’s filings-based review.
- FY25 revenue: ₹103.5 crore, up 3.7% year-on-year against FY24 — a slowing growth rate for a company still years from an IPO.
- FY25 net loss: ₹24.2 crore, meaning the company spent roughly ₹1.23 for every ₹1 of revenue it booked that year, per Inc42.
Where the money comes from
- By campaign type: individual medical campaigns (0% platform fee, tip-funded) make up the bulk of campaign count, per the company’s own fundraiser numbers, while pooled and NGO campaigns sit on a separate, higher fee schedule — meaning campaign volume and fee revenue do not move together.
- By geography: ImpactGuru’s payment terms separately price domestic (INR) and international (USD) donations, the latter carrying an extra per-transaction and wire fee, which signals a meaningful share of giving comes from donors outside India, consistent with the company’s long-standing push into Gulf markets backed by Shorooq Partners.
- By scale: the company states a cumulative “50 lakh+” donor base and “50,000+” patients funded on its own site (accessed September 2026), without a fixed start or end date attached to either number, which is why they are presented here as company-stated lifetime figures rather than a single fiscal year’s activity.
- By workforce: ImpactGuru employed about 578 people as of August 2025, down 24% year-on-year, per Tracxn — a contraction that runs alongside, not against, the FY25 loss.
- The surprise: the product donors associate most strongly with ImpactGuru — a free personal medical campaign — is structurally the one contributing least to direct platform-fee income; the company’s actual revenue is more dependent on payment-processing margins, the NGO fee tier, premium add-ons and the newer insurance and lending cross-sell than on the fundraising product itself.
The risks
- Verification cannot outrun urgency. A platform built to disburse money within hours of a diagnosis cannot also run a forensic audit before releasing funds. That gap is exactly what the Baby Inara complaint exposed in 2024-25: an allegation of diverted funds became a criminal case before it could be independently confirmed either way, and it took a police investigation, not the platform’s own controls, to close it (NewsX, November 2024; Republic World, 2025). The mechanism — pay first, verify later — is inherent to the product, not a one-off failure.
- The “0% fee” pitch does not match donor experience. ImpactGuru’s Trustpilot page carried a 2.9-out-of-5 rating from 133 reviews as of September 2026, with 60% of reviewers giving one star. The recurring complaints are not about the medical need itself but about aggressive follow-up calls after an initial donation, unclear deductions from raised amounts, and slow fund disbursement requiring repeated document submissions (Trustpilot, accessed September 2026). A headline fee of zero, sitting next to gateway charges and NGO-tier fees that are real but less prominently marketed, is a recurring source of the “you lied about the fee” complaint.
- The core product’s growth has slowed while losses have not. FY25 revenue grew just 3.7% over FY24 even as the company posted a ₹24.2 crore net loss and cut headcount by roughly a quarter year-on-year (Inc42; Tracxn). Diversifying into insurance and lending under the CarePal brand gives ImpactGuru new revenue lines, but it also means the company is now competing in two heavily regulated, capital-intensive categories — insurance distribution and consumer lending — while its founding product is still not consistently profitable.
The takeaway
ImpactGuru’s founders bet that removing a fee would remove the biggest reason people don’t ask strangers for help with a hospital bill, and on the evidence of a 50-lakh-strong donor base, the bet largely paid off. But “free” was never actually free — it moved the cost elsewhere, into payment gateways, into a separate NGO fee tier, into premium add-ons, and eventually into a loss the company has to fund some other way. The lesson generalises past crowdfunding: any platform that competes by giving away its most visible price point is not eliminating cost, it is relocating it, and the parts of the business built to absorb that cost — trust, verification, cross-sell — end up mattering more than the free feature that got users in the door.
Frequently asked questions
Is ImpactGuru a legitimate platform to donate through?
ImpactGuru is a functioning, funded company operating since 2014 with disclosed investors and filed financials, not an anonymous scheme. It has also faced a criminal complaint alleging fund diversion in one specific 2024 campaign, which Mumbai police closed in 2025 after finding no supporting evidence (Republic World, 2025). Donors should still verify a specific campaign’s documentation rather than trust the platform’s brand alone, which is the same advice that applies to any crowdfunding site.
Does ImpactGuru really charge 0% fees?
It charges 0% platform fee on personal medical campaigns and relies on optional donor tips instead, but payment-gateway charges of roughly 2.5-4% plus GST still apply, and registered NGO or pooled-cause campaigns sit on a separate, higher fee tier, per the company’s own pricing pages.
Who founded ImpactGuru and when?
Piyush Jain and Khushboo Jain, a husband-and-wife team, founded ImpactGuru in 2014, incubating the idea at Harvard’s Innovation Lab before building it out in Mumbai; the company was incorporated in January 2015.
How much funding has ImpactGuru raised, and who are its investors?
Tracxn’s tracker puts total disclosed funding at $21.2 million across nine rounds, from backers including RB Investments, Apollo Hospitals Enterprise and Shorooq Partners, with a reported valuation of about $92.3 million as of a February 2025 round — a single-source estimate, not a company-confirmed figure.
Is ImpactGuru profitable?
Not as of its most recent disclosed year. ImpactGuru posted revenue of ₹103.5 crore against a net loss of ₹24.2 crore in FY25, with revenue growth slowing to 3.7% year-on-year, per Inc42’s review of its filings.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- YourStory, “Khushboo Jain of ImpactGuru.com on how the platform raised over Rs 15 Cr to help daily wagers, others amid COVID-19”, November 2020
- Startup Talky, “Success Story of ImpactGuru – Crowdfunding Startup”, accessed September 2026
- Tracxn, “ImpactGuru – Funding Rounds & List of Investors”, accessed September 2026
- Tracxn, “ImpactGuru – Company Profile, Team, Funding, Competitors & Financials” (headcount, competitors), accessed September 2026
- Inc42, “Impact Guru Financials 2026 – Revenue, P&L & Cash Flow”, accessed September 2026
- CB Insights, “Impact Guru – Stock Price, Funding, Valuation, Revenue & Financial Statements”, accessed September 2026
- NewsX, “FIR Lodged Against CEO Of Crowdfunding Platform, Two Others In ₹4.5 Cr Fraud Case”, November 2024
- Republic World, “Matunga Station of Mumbai Police Files Closure Report in Court Dismissing Allegations in FIR Against Impact Guru CEO Piyush Jain and Baby Inara’s Parents”, 2025
- Free Press Journal, “Mumbai: Impact Guru Refutes Allegations Of Fund Misuse For Child’s SMA Treatment, Clarifies ₹2.2 Crore Raised”, 2024
- Trustpilot, “Impact Guru Reviews”, accessed September 2026
- ImpactGuru.com, homepage and Medical Crowdfunding page, accessed September 2026
- ImpactGuru.com, pricing and fee-schedule pages, accessed September 2026
- The Print / Business Standard press release, “Impact Guru forms Parent Brand CarePal Group, a one-stop-solution for healthcare financing”, May 2023
- Trading Economics, USD/INR exchange rate, 18 September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.